Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TS Blood Collection Kit, a product of Tasso-SNBL, Ltd., received certification as a controlled medical device under Japan’s Pharmaceuticals and Medical Devices Act. This certification was conducted by a third-party certification body registered with the Ministry of Health, Labour and Welfare (MHLW) and confirms the product’s safety, performance, and quality control system comply with relevant regulations.  

The TS Blood Collection Kit integrates Tasso’s signature lancet technology with a compatible collection reservoir to deliver a virtually painless, self-administered solution for collecting high-quality blood samples. Designed for use anywhere, including at home, the kit minimizes patient discomfort while ensuring reliable results for healthcare providers.  

With Japan facing an aging population and ongoing healthcare workforce shortages, this certification enables new ways to close critical gaps in access. By allowing patients to self-collect high-quality blood samples at home, the technology could support earlier detection, continuity of care through telemedicine, and a reduced reliance on in-clinic blood draws, thus easing the strain on Japan’s healthcare workers and giving patients more access to care.  

Tasso-SNBL, Ltd. was established in March 2025 as a joint venture between Tasso and Shin Nippon Biomedical Laboratories, Ltd. The company holds the exclusive rights to import and distribute Tasso capillary blood self-collection devices in Japan.  

“This certification marks an important step for our joint venture with SNBL and for patients across Japan,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “As healthcare needs continue to evolve worldwide, Tasso remains committed to delivering patient-centric innovations that expand access, improve comfort, and reduce the burden on healthcare systems.”